Cite
HARVARD Citation
Berlin, J. et al. (n.d.). 385 A first-in-human study of lemzoparlimab, a differentiated anti-CD47 antibody, in subjects with relapsed/refractory malignancy: initial monotherapy results. Journal for immunotherapy of cancer. pp. A233-A234. [Online].